DARE
Dare Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.72
+1.11%Aug 31, 2026, 12:44 UTC
Daré Bioscience announced a new NIH funding award of approximately $908,000 to advance DARE-PTB2 for the prevention of preterm birth, with potential for an additional future-year grant of approximately $1.3 million.
Source:Aug 26, 2026, 12:45 UTC
Daré Bioscience launched DARE to PLAY Sildenafil Cream, a 503B compounded version of its proprietary sildenafil cream formulation, while continuing to advance the product toward the FDA's 505(b)(2) regulatory pathway.
Source:Aug 17, 2026, 00:00 UTC
Dare Bioscience, Inc. signed a registered direct offering and concurrent private placement to raise approximately $6.0 million in gross proceeds, offering common stock, pre-funded warrants, and Series A and Series B common purchase warrants, with closing subject to customary conditions and stockholder approval for warrant exercise.
Aug 13, 2026, 00:00 UTC
Dare Bioscience, Inc. reported its Q2 2026 financial results, with total revenue of $0.2 million and a net loss of approximately $3.0 million, including a diluted EPS of -$0.20.
Source:Jul 1, 2026, 12:55 UTC
Daré Bioscience launched its product Flora Sync LF5 through its direct-to-consumer platform.
Source:Jun 12, 2026, 00:00 UTC
Dare Bioscience, Inc. elected Gregory W. Matz, CPA and Sabrina Martucci Johnson as Class III directors effective June 11, 2026.